CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSEAmerican:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Medical%20lab%20microscope%20chemistry%20biology%20test%20by%20Shutter2U%20via%20Adobe%20Stock.jpeg)
/AI%20(artificial%20intelligence)/An%20aerial%20view%20of%20a%20data%20center%20cooling%20system%20by%20Sepia100%20via%20Adobe%20Stock.jpeg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
